Navigation Links
Derma Sciences To Present at Rodman & Renshaw's Eleventh Annual Healthcare Conference
Date:9/2/2009

PRINCETON, N.J., Sept. 2 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, will present at Rodman & Renshaw's Eleventh Annual Healthcare Conference taking place September 9 - 11, 2009, at the New York Palace Hotel. Edward J. Quilty, Chairman and Chief Executive Officer will give the company presentation on Friday, September 11, 2009, 9:10AM EDT in the Fahnestock Salon (fifth floor). Additional information regarding the conference can be found at http://rodm.com/conferences?id=30.

Expected to welcome 3,500 guests and include presentations by over five hundred companies, the Conference will be attended by investors, venture capitalists, company executives, medical experts, scientists, and other industry leaders. To access a live audio webcast or the subsequent archived recording, log on to http://www.wsw.com/webcast/rrshq15/dsci.ob. Please connect to the website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound care products. Its key product, MEDIHONEY(R), is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was the focus of a positive large-scale randomized controlled trial on leg ulcers. Derma's recently FDA cleared BIOGUARD(TM) Barrier Dressing is the Company's latest new product entrant into the $14 billion global wound care market. The barrier technology was licensed from Quick-Med Technologies, Inc. in Q1 of 2007. Derma also has in development DSC127, a novel angiotensin analog for accelerated wound healing and scar reduction. DSC127 was licensed from the University of Southern California in Q4 of 2007. Patient enrollment for a Phase II study began in Q4 of 2008. Results from this study are expected to be submitted to the FDA in Q2 of 2010.

For more news and information on Derma Sciences, Inc., please visit www.IRGnews.com/coi/DSCI where you can find the CEO's video, a fact sheet on the company, investor presentations, and more.

Forward-Looking Statements

Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's fillings with the Securities and Exchange Commission.

    Contact:

        Derma Sciences, Inc.
        Edward J. Quilty
        Chairman and CEO
        equilty@dermasciences.com
        (609) 514- 4744

        Contact:

        The Investor Relations Group
        212-825-3210
        Investor Relations:
        Rachel Olson
        or
        Michael Crawford
        Or
        Media Relations:
        Susan Morgenbesser


'/>"/>
SOURCE Derma Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dermal Filler Procedures Jump 30% at Center For Cosmetic and Plastic Surgery
2. Painless, Bruise-free Dermal Filler Injections
3. IDRI to Use NanoPass Microneedle Technology for Intradermal Vaccines and Diagnostic Skin Tests
4. Solve Skin Conditions and Receive Hair Loss Treatment from Home with New Line of Medical Devices Called Dermaray
5. Portland Dermatologists to Show LPGA Safeway Classic Fans How to Play Safe in the Sun
6. Benjamin S. Gonzalez, MD Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler
7. CSC Announces Agreement to Provide Billing Service to Colorado West Dermatology
8. Derma Sciences Reports Second Quarter 2009 Results
9. Illinois Dermatologists Tee Up for Sun Safety at Two World-Class Golf Championships
10. Rodan + Fields Dermatologists Launch National Hispanic Outreach Campaign
11. Making The Outdoors Safer for Communities: The American Academy of Dermatology Announces 2009 AAD Shade Structure Program Grant Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2017)... ... August 20, 2017 , ... State Farm Neighborhood Assist® ... national causes up for a $25,000 grant. If the initiative wins, Gals Lead – ... will expand into the Tri-County area of St. Mary’s, Calvert and Charles Counties. The ...
(Date:8/19/2017)... ... August 18, 2017 , ... ... a transparent, verifiable database to help the cannabis industry move towards greater legitimacy. ... to deliver a faster technology with lower fees. Paragon will build a fully ...
(Date:8/19/2017)... ... August 19, 2017 , ... Praeclarus Press has launched ... illustrations show the diversity of the breastfeeding mothers, using bright colors and ... sizes. These illustrations are also available on tote bags, notepads, smartphone cases, clocks, ...
(Date:8/19/2017)... ... 19, 2017 , ... “Congratulations! It's A Boy! God’s Gift: A Story of ... and God. “Congratulations! It's A Boy! God’s Gift: A Story of Love” is the ... New York. , Published by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s new ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... International, LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport ... a definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc (NASDAQ: ... agreements to resolve virtually all known U.S. mesh product ... to resolve the known remaining U.S. claims at reasonable ... beginning in the fourth quarter of 2017 and continuing ... its second quarter 2017 results, the Company intends to ...
(Date:8/2/2017)... BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital in ... team to proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, Tru-D ... UVC light energy to kill deadly pathogens such as C. diff , MRSA, MERS, ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:7/31/2017)... 31, 2017 Three Tru-D SmartUVC robots have arrived ... Korea . Tru-D, short for "Total Room Ultraviolet Disinfection," is a ... an environmental services (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs ... "Although the BAACH has a very ...
Breaking Medicine Technology: